Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

MoonLake Immunotherapeutics is for sale? This sounds like a cry for help, STAT's Adam Feuerstein writes.

Stocks were rising Tuesday and the Nasdaq Composite turned higher for the year even as uncertainty over global trade ...

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it ...

Constellation Energy (CEG) has inked a 20-year deal to provide tech giant Meta Platforms (META) with power from its clean ...

MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports.

Short interest in MoonLake Immunotherapeutics (NASDAQ:MLTX) decreased during the last reporting period, falling from 6.63M to 6.10M. This put 21.56% of the company's publicly available shares short.

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than US$3 billion, the Financial Times ...